Article
02 Apr 2026
Formycon And Regeneron Settle European Aflibercept Biosimilar Litigation
AUTHORS CONTENT
Article
26 Feb 2026
Formycon And Lotus Expand Collaboration In Asia-Pacific Region To Pembrolizumab Biosimilar
Article
17 Dec 2025
FDA Approves BMS's BREYANZI As First MZL CAR T Therapy
Article
11 Nov 2025
Hikma Launches Ustekinumab Biosimilar STARJEMZA
Article
07 Oct 2025
FDA Approves Seventh Denosumab Biosimilar: Richter And Hikma's Enoby And Xtrenbo
Article
01 Sep 2025
FDA Approves Expanded Indication For Celltrion's AVTOZMA For The Treatment Of Cytokine Release Syndrome
Article
04 Aug 2025
Fresenius Files Two IPRs Against Regeneron Aflibercept Patents
Article
05 Dec 2024
Update On Pending Denosumab BPCIA Litigations
Article
28 Oct 2024
GlaxoSmithKline And Northwestern Sue Moderna For Patent Infringement In Trio Of Lawsuits
Article
19 Sep 2024
WHO Prequalifies Bavarian Nordic's MVA-BN As First Vaccine Against Mpox
Article
17 Jan 2024
Issue 43: PTAB Trial Tracker
Article
20 Dec 2023
FDA Approves First Cell-Based Therapies For Treatment Of Sickle Cell Disease
Article
31 Jul 2023
Sandoz Invests In New Biosimilar Manufacturing Facility
Article
15 Mar 2023
Janssen Seeks A Preliminary Injunction In BPCIA Ustekinumab Case Against Amgen
Article
02 Nov 2022
Biogen Seeks A Preliminary Injunction In Natalizumab BPCIA Case Against Sandoz
Article
10 Aug 2022
Denosumab Clinical Trial Updates
Article
11 Jul 2022
Mylan Voluntarily Recalls Additional Batch Of Biosimilar Insulin Glargine Pens Due To Potential Missing Labels
Article
01 Jun 2022
Outlook Therapeutics To Revise Ophthalmic Bevacizumab BLA In Light Of FDA Request
Article
28 Apr 2022
Celltrion To Enter U.S. Humira Biosimilar Market Following Patent Agreement With AbbVie
Article
23 Mar 2022
FDA To Hold Final Assessment Of The Program For Enhanced Review Transparency And Communication In The Biosimilar User Fee Act